New research reveals how Zoledronic acid dismantles EMT's machinery by targeting NEDD9, silencing prostate cancer's invasive voice.
Discover how prostate cancer disables the PMEPA1-NEDD4 molecular brake system that regulates androgen receptor stability, leading to treatment resistance.